Every Hemophilia A Product and Their Death and Adverse Reactions Data

Below you will find a current list of Hemophilia A products along with their death and adverse reactions data.

By looking at this data, emicizumab (Hemlibra) has the most negative data in such a short period of time since FDA approval.

BRAND

DEATHS

ADVERSE REACTIONS

FDA APPROVAL

HEMLIBRA

54

700

OCTOBER 2018

ADVATE

133

2,572

DECEMBER 2011

ADYNOVATE

15

280

NOVEMBER 2015

AFSTYLA

2

46

MAY 2016

ELOCTATE

23

488

JUNE 2014

ESPEROCT

1

6

FEBRUARY 2019

JIVI

1

50

AUGUST 2018

KOGENATE

46

1,316

MARCH 2009

KOVALTRY

15

197

MARCH 2016

NOVOEIGHT

15

89

OCTOBER 2013

NUWIQ

2

21

SEPTEMBER 2015

RECOMBINATE

27

481

UNKNOWN

XYNTHA

28

355

FEBRUARY 2008